Phase II study of sunitinib in men with advanced prostate cancer. - Wikidata - awgldk - TriplyDB

Phase II study of sunitinib in men with advanced prostate cancer.

Phase II study of sunitinib in men with advanced prostate cancer.

http://www.wikidata.org/entity/Q39983597

about

Progress of molecular targeted therapies for prostate cancers Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients.Angiogenesis inhibition in prostate cancer: current uses and future promises.Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.Evolving role of bone biomarkers in castration-resistant prostate cancer.Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).Targeted therapy in prostate cancer.A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.Circulating endothelial progenitor cells in castration resistant prostate cancer: a randomized, controlled, biomarker study.Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer.Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.MET and VEGF: synergistic targets in castration-resistant prostate cancer Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients.A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries.Emerging targeted therapies for castration-resistant prostate cancer.Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures.Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells Perspectives on treatment of metastatic castration-resistant prostate cancer.Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer Pazopanib: therapeutic developments.Sunitinib Treatment Enhances Metastasis of Innately Drug-Resistant Breast Tumors.Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials.Castrate-resistant prostate cancer: therapeutic strategies.Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer.Docetaxel-based combination therapy for castration-resistant prostate cancer.Antitumor effect of sunitinib in human prostate cancer cells functions via autophagy.Future directions in castrate-resistant prostate cancer therapy.Recent developments in prostate cancer biomarker research: therapeutic implications.Castration-resistant prostate cancer: targeted therapies.Current treatment strategies for castration-resistant prostate cancer Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.

P2860

Q26823014-86841957-132E-41A7-B3B7-9C4883EE1474 Q28074295-7BB82969-B26C-4697-AD73-6A51DA0DADAF Q28247245-E0F96384-1DEA-432A-9962-DE88A251F7DE Q33395780-7C4E8262-756E-4B79-A943-488C1587E3A6 Q33652297-9FA83947-AE80-4796-9359-35884E4E00C6 Q34005875-B7AD84AC-B064-4E4B-BDF8-E5BC19EEC26E Q34023877-79864485-C55C-4834-9F7E-CA467B23A108 Q34554398-885F3745-C392-45AD-9FF0-50F1B9F38F8F Q34587714-E502D48B-44F7-4A81-9816-C84D529987F2 Q34634763-81963091-0A4B-49D6-AF30-1B8B8347303D Q35034020-12E24AC9-B01F-4592-878C-530D95C35767 Q35155251-B7628960-A11B-4559-B31D-DA304E50A0CF Q35302321-DE8E7B70-8E07-4B2E-9FAD-63242E09E590 Q35508739-F0C00D55-65AA-4AA5-A208-98F7C74C6030 Q35555303-F6E30746-10C2-4A33-8D32-7747DCE28D1C Q35575488-BDE60552-4C60-4009-BBD4-936C675AFA65 Q35623311-7580F9C3-E8BC-4F1D-A9A6-88875675F5F7 Q35879889-D21513DA-A5FC-4818-8505-65B178CEDA61 Q35985270-4590C0A2-7586-41D0-9471-4DA28A11A39B Q35999255-C8B91A4B-DDDD-40D1-A1B2-8C76FCF33EFC Q36181578-97BAC7E8-393D-4B9B-BA5D-CA7E6C3287AA Q36378963-BD812266-C08A-44ED-A535-1F493DCD04E2 Q36871685-2E1DE65A-79C6-4101-B658-B1A44BB74506 Q36931715-7E7EBC84-8EF5-46A7-A92B-AA2595546100 Q36934749-4561DB31-9E27-42E1-BD0C-138C5FBA903B Q37127044-D510AC94-EEB6-4C25-8487-DFB0446874EA Q37193613-77280DB5-FF7F-4B5E-BEB3-4689F05F1321 Q37642770-C5F5740F-9B31-444A-84C8-559C8C21F83D Q37660355-7A156AF9-8FD1-49EE-B3DB-483079AED54B Q37705424-6B19923C-77E7-4146-B0F2-A97BC747CEFA Q37716009-32F7CB25-1C4B-413D-B2C5-EADB0B452BCF Q37720488-713D4C3E-443B-4F33-BDC1-FB71090F552B Q37721016-202936EC-3F6F-4373-B0F6-722A172D62A2 Q37734570-BC902507-67F8-4AE6-BED6-84FA06B86FB0 Q37826274-A31147DA-EC55-453E-A6CC-BEB8E14C04DC Q37827186-325A9E97-760A-4A9F-89F2-3652A9897F4A Q37856646-9B75F9AE-0D7C-4525-9D16-C5C107F76160 Q37860950-FFC1CE30-937C-411A-AEE0-BD28C4D364E7 Q37876194-6621C6F5-34DE-4B79-BEEC-9D3A2F01CFA6 Q37968256-B143C206-F22D-4EA2-8D92-2AF7A6D7E58A

P2860

Phase II study of sunitinib in men with advanced prostate cancer.

http://www.wikidata.org/entity/Q39983597

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Phase II study of sunitinib in men with advanced prostate cancer.

@en

Phase II study of sunitinib in men with advanced prostate cancer.

@nl

type

label

Phase II study of sunitinib in men with advanced prostate cancer.

@en

Phase II study of sunitinib in men with advanced prostate cancer.

@nl

prefLabel

Phase II study of sunitinib in men with advanced prostate cancer.

@en

Phase II study of sunitinib in men with advanced prostate cancer.

@nl

P1433

Q39983597-3BFF9500-A8A3-4BDA-B789-136D703971AE

P1476

Q39983597-8B218CE5-07D9-4FF0-942F-805AE8E0A917

P2093

Q39983597-121156FD-A016-4CD9-B17C-88B46E790EC9

Q39983597-5C9D7311-2A31-4552-AF41-5579AD501BCD

Q39983597-88BE996B-A3B3-4984-9356-4D26B6222C10

Q39983597-9452727D-74F0-4461-BABD-B0E29E7A9C1D

Q39983597-B605EE51-51AF-424E-83A1-753992F9576E

Q39983597-B90C0909-8C7B-4F6A-8D40-682FA46CF4BE

Q39983597-E7B3031A-D8AB-4DB5-A56F-25010F346451

P2860

Q39983597-09EC809A-240A-4DCE-B360-539F9ADC1356

Q39983597-1454BF7F-4DF7-4033-A602-11CE45FBDC4D

Q39983597-159D054D-B289-4554-869E-7CF9D3C5E271

Q39983597-1EE04794-74F5-4561-BB16-B03EE80619F8

Q39983597-247FED4A-09A9-41ED-81F3-34B792175C99

Q39983597-264BDCAA-1D02-4EEC-9279-1CF3C4A04C3A

Q39983597-3A21F262-719B-42D3-8641-43004D62AA8B

Q39983597-4BB60334-053E-4F2B-AC60-C33DFA744CCC

Q39983597-5A8B0294-F125-4AD7-96F4-C695D9CE3E93

Q39983597-5D5CFCA9-B0F6-4F53-B980-E6488AFFD377

P304

Q39983597-C95EB71E-375B-4F00-AC14-43D42D44CFDF

P31

Q39983597-75570F29-AC8A-4EE7-9EF0-70828CAD2768

P356

Q39983597-3960B5BD-01E8-417E-AF0F-426108045B9D

P433

Q39983597-5E1B036F-214A-401B-B726-B92EE0059C40

P478

Q39983597-58C401D4-E095-48DC-95E1-755D5EBA4BA3

P50

Q39983597-6E794860-EF5B-494E-819B-27FEC65BB773

Q39983597-8F9C31B1-26B6-482F-8A52-515C9CDEDEDF

Q39983597-BF2186AD-E8F4-48E4-AB9A-AE324CCF2ADE

P577

Q39983597-DE55BE44-808A-42EA-AA12-13FA1556215B

P5875

Q39983597-2849FD12-6A67-4365-AAB0-0D61855B2B60

P698

Q39983597-EEE3B9D6-5FBF-4FB9-AE04-F8E5DB67EB28

P932

Q39983597-94677F0E-8A1C-48E2-B05F-3BB009AFA276

P356

P1433

Annals of Oncology

P1476

Phase II study of sunitinib in men with advanced prostate cancer

@en

P2093

B Spicer

http://www.w3.org/2001/XMLSchema#string

C Gurski

http://www.w3.org/2001/XMLSchema#string

D S Kaufman

http://www.w3.org/2001/XMLSchema#string

K Olivier

http://www.w3.org/2001/XMLSchema#string

M Dror Michaelson

http://www.w3.org/2001/XMLSchema#string

M M Regan

http://www.w3.org/2001/XMLSchema#string

M R Smith

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2008

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Leptin is associated with increased prostate cancer risk: a nested case-referent study.

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF.

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

P304

913-920

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDP111

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Philip W. Kantoff

M. Dror Michaelson

P577

2009-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24378780

http://www.w3.org/2001/XMLSchema#string

P698

19403935

http://www.w3.org/2001/XMLSchema#string

P932

2674960

http://www.w3.org/2001/XMLSchema#string